Use of human fibroblast-derived (beta) interferon in the treatment of epidemic adenovirus keratoconjunctivitis.

Topical application of human fibroblast-derived (beta) interferon (HulFN-beta) has been used in treatment of epidemic keratoconjunctivitis due to adenovirus. Patients received a total of 1-2 x 10(5) reference units of HulFN-beta per day, divided into 8-10 drops. Control patients received corticosteroid therapy or a placebo containing human serum albumin, with the same administration schedule. The severity and evolution of symptoms was analyzed according to a number of clinical criterias. The results indicate that in the interferon-treated group the length of the disease was reduced from an average of 27 days to 6.5 days. The number of cases in which keratitis occurred as a complication of the disease was reduced in the interferon-treated group to 10%, as opposed to 57% in the control group. Doses of interferon lower than 5 x 10(4) units per day, were not effective to prevent keratitis.

RCT Entities:   Population Interventions Outcomes